Is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) overvalued? · P/E 44, rev $2.79B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page asks whether Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) looks expensive on cached numbers — not a short thesis.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next AMRX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the AMRX stock page for the full model, not this heading.
Not investment advice.